Industry News
Novogen pleased by cancer drug results
Trials of Novogen's (ASX:NRT) anti-cancer drug phenoxodiol have shown it significantly delays tumour progression in men suffering from late-stage hormone refractory prostate cancer and produces anti-cancer responses in women with cervical cancer. [ + ]
Good press drove October biotech enthusiasm: Intersuisse
Biotech shares bucked the trend during the month of October - the Intersuisse biotechnology index gained 6.6 per cent in contrast to the All Ordinaries and the Nasdaq Biotech Index, which fell by 3.9 per cent and 3.8 per cent respectively. [ + ]
Aust CROs tell of boom in clinical trials work
Ruth Beran spoke with Australian contract research organisations and found that there is strong demand for Australian clinical trials, both from within Australia and also from overseas. [ + ]
Collaborators seek parasite invasion blockers
A malaria research team, including WEHI Structural Biologist, Professor Ray Norton, has received a US$1 million grant from the US National Institutes of Health to develop more effective malaria treatments.
[ + ]New research shows Aussie lizard bites can really hurt
Australian venom researchers have uncovered a 200-million year old secret: Australia's goannas and bearded dragons, Indonesia's giant Komodo dragon, and their iguana cousins, are more closely related to snakes than to other lizards -- and they're venomous. [ + ]
Hatchtech awarded $2.4m grant
Unlisted Melbourne biotech Hatchtech has been awarded a AUD$2.4 million AusIndustry Commercial Ready grant to support its head lice treatment R&D program. [ + ]
Tissue Therapies raises $1.6m, announces SPP
Brisbane biotech Tissue Therapies (ASX:TIS) has completed a placement to investors, raising AUD$1.6 million before costs. [ + ]
Premier Bionics division gets Hong Kong order
Medic Vision, a wholly owned subsidiary of Premier Bionics (ASX:PBI), has received an initial order for its surgical simulation products worth almost $460,000 from a hospital in Hong Kong. [ + ]
Cryptome to acquire HealthLinx
Melbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has entered a non-binding terms sheet to acquire HealthLinx, a privately-held diagnostics specialist with lead candidates targeting ovarian cancer and complications in pregnancy. [ + ]
Positive performance for Australian life sciences sector
The Australian life sciences sector has picked up with small cap stocks seeing positive growth in the last quarter, according to the November edition of PricewaterhouseCoopers' quarterly BioForum report. [ + ]
Alchemia options worth $2m exercised
The Dow Chemical Company has exercised AUD$2 million worth of options in manufacturing partner Alchemia (ASX:ACL). [ + ]
SCS Japanese affiliate signs cell therapy agreement
Stem Cell Sciences KK (SCS KK), a Japanese affiliate of Stem Cell Sciences (AIM:STEM, SCS), has signed a worldwide exclusive license agreement with the University of Nice to commercialise tissue stem cells that may have therapeutic application in degenerative diseases such as Duchenne Muscular Dystrophy (DMD). [ + ]
Metabolic reports successful phase I trials
Melbourne biopharma Metabolic (ASX:MBP) has announced plans to take its ACV1 conotoxin analgesic into phase IIa clinical trial in volunteers with chronic neuropathic pain next year. [ + ]
Cancer breakthrough for UQ researchers
University of Queensland researchers have reported spectacular success in killing cervical cancer cells and preventing the cancer in female mice, using RNA-interference (RNAi) therapy. [ + ]
Crown Scientific is now 100% Australian owned
Cospak bought Crown Scientific effective from 30 June 2005. Cospak is a leading national supplier of glass and plastic containers to the Australian market with modern offices and warehouses in all capital cities.
[ + ]
